Regulatory Affairs Associate, Mayne Pharma (Canada) Inc. 2 October 2006. Personal communication. 46. Thyrogen Product Monograph. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) BCG (Tice substrain) 1 mL preservative 1 to 8108 2 h F (PFL)27 transfer from vial to 2 h F27 - cytotoxic3 50 mg = 1 to 8 x 108 free NS for CFU/vial27 60 mL syringe, rinse - overfill unknown CFU injection27 vial with another 1 mL - protect from (Hospira/Organon) NS. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) 0.5 2.0 mg/mL210 24 h F, RT210 50 mL* NS, D5W, NS, D5NS, Ringers, Ringers Lactate210 Vinorelbine 10 mg/1 mL N/A211 10 mg/mL211 discard unused syringe: 1.5-3.0 24 h F, RT211 - cytotoxic3 50 mg/5mL portion211 mg/mL in D5W or - label with: (Pierre Fabre Pharma NS211 WARNING: FOR Canada) INTRAVENOUS (F)(PFL) USE ONLY no preservative211 FATAL IF GIVEN BY OTHER ROUTES204,205 0.5-2.0 mg/mL211 24 h F, RT211 NS, D5W, NS, D5NS, Ringers, Ringers Lactate211 BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 59/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 60. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) 38 mg/mL-0.1 mg/mL 48 h RT13,119 NS or D5W115,118 BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 27/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 28. J Oncol Pharm Pract 2007;13(1):27-31. These CBD candies offer a simple and flexible . BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Fludarabine 50 mg 2 mL SWI102 25 mg/mL102 48 h F or RT13,49 dilute to maximum of 48 h F, RT13,49 - cytotoxic7 (Berlex) 1 mg/mL102,103 (F) no preservative102 100 mL*NS or D5W102 Fludarabine 50 mg N/A 25 mg/mL104 discard unused dilute to maximum of 48 h F, 24 h RT104 - cytotoxic7 (Novopharm) portion104 1 mg/mL104 (F) no preservative104 100 mL*NS or D5W BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 23/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 24. Toronto, Ontario; undated. 189. 70. Maureen Coughlin BSc Pharm. 24. The pharmaceutical manufacturers usually provide data on how to prepare their products and the associated physicochemical stability. Natalie Groves BScN. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) 0.3 million IU/mL123 24 h F, RT124 50 mL NS123 Interferon Alfa -2b 25 million IU/2.5 mL N/A 10 million IU/mL123 48 h F13,123 syringe123 2 d F13,124 - cytotoxic7 (Schering) (F)(or up to 7 days at RT before use) no preservative123 0.3 million IU/mL123 24 h F, RT124 50 mL NS123 Interferon Alfa -2b 10 million IU 1 mL supplied 10 million IU/mL123 24 h F123 syringe123 24 h F, RT124 - cytotoxic7 (Schering) diluent (SWI) 123 (F) no preservative123 do not shake; roll to reconstitute123 > 0.1 million IU/mL124 48 h RT11,13 100 mL NS125 BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 29/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 30. Beryl Chan. Regulatory Affairs Associate, Fluorouracil, Mayne Pharma Canada; reference # FEB-43-2005.February 16, 2005. Photo: Andreas Neumann. 108. 90. - normal saline no preservative47 polyolefin, may be used to polyethylene, flush the line47 ethylene vinyl - solution may acetate, DEHP contain white plasticized PVC, PVC particulates which bag, or glass47 do not affect product quality47 BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 11/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 12. Can J Hosp Pharm 2003;56 (Suppl PPC):S51. DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status) Reconstitute With: To Give: Vial Stability. Care has been taken to ensure accuracy of the information, however it is not intended to replace the specific recommendations of physicians in your institution. BCCA Provincial Systemic Therapy Program. 162. Many BC immigrants are not getting screened for breast cancer, 10th Annual Ride to Conquer Cancer raises $10.6 million for BC Cancer, Join the Mammolanche and reduce the risk of breast cancer mortality, Monoclonal Gammopathy of Unknown Significance (MGUS), Pain & Symptom Management/Palliative Care, Symptom & Side Effect Management Resource Guide, Chemotherapy Order Assessment Case Studies, Skin Cancer Prevention & Early Diagnosis Courses, General Practitioner in Oncology Education Program, Copyright 2023 Provincial Health Services Authority. 52. 82. ; 2006. Vancouver, BC; February 2002. Paclitaxel Package Insert. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 418-420. Hoffmann-La Roche Limited. This manual is designed to be a general reference in the appropriate use and dosing of chemotherapy drugs. Side effects might include headache, facial flushing and indigestion. Procytox Package Insert. 41. Supervisor, Hospira Canada Clinical Support. Trissel's2 Clinical Pharmaceutics Database (Parenteral Compatibility) [database on the internet]. Celgene. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Oxaliplatin 50 mg/10 mL N/A 5 mg/mL157 discard unused 0.2-1.3 mg/mL158 0.2-1.3 mg/mL: - cytotoxic7 100 mg/20 mL portion157 14 d F, 48 h RT159,87,158 - do NOT use 200 mg/40 mL 1.32 mg/mL157,158 aluminum- (Sanofi-Aventis) 1.3-2 mg/mL: containing needle, (RT)(PFL) 250500 mL D5W157 48 h F, 24 h RT157 syringe or no preservative157 tubing157 do NOT use NS or other chloride- containing solution157 do NOT use aluminum-containing needle and syringe157 BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 42/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 43. BC Cancer Chemotherapy Preparation and Stability Chart version 2.00 10/47 Activation Date: 2 March 2006 Revised Date: 1 May 2018. Montreal, Canada; 2002. BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status) Reconstitute With: To Give: Vial Stability Product (for IV bag size selection, see Notes) Product Stability Special Precautions/Notes Leucovorin 50 mg/5 mL 5 500 mg/50 mL 5 (Teva) (F)(PFL) no preservative472 h NS 186. Deerfield, Illinois; 19 August 2008. Mississauga, Ontario; 5 March 2009. 184. 144. Vancouver, British Columbia: BC Cancer Agency; 1 August 2000. Ro 4876647 Avastin Investigator's Brochure. Repchinsky C. Cisplatin CPhA monograph, Compendium of Pharmaceuticals and Specialties. 210. Erfa Canada Inc. Daunorubicin injection product monograph. John Korontzis. Manjinder S Kang. Mississauga, Ontario; 25 November 2004. Trissel LA. Dilute to a concentration of 1,000 units/mL, 2,000 units/mL, 5,000 units/mL, or 10,000 units/mL, using SWFI or NS. Personal communication. Wyeth Canada. Novopharm Limited. Eli Lilly Canada Inc. Gemzar Package Insert. Montreal, Quebec; 2002. Mississauga, Ontario; July 1997. Mayne Pharma (Canada) Inc. Scientific Affairs Manager, Irinotecan. You are encouraged to also consult other current references as they become available. May 2010. Scarborough, Ontario; 8 November 1996. Toronto, Ontario; 18 April 2006. 133. Fazer o download agora mesmo de 41 BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Leucovorin 1 1,2 50 mg/5 mL N/A 10 mg/mL discard unused syringe 8 h RT 1 (GMP) portion Intron A (interferon alpha-2b). Vancouver, British Columbia: BC Cancer Agency; 1 May 2001. Montreal, Canada; 2000. Chemotherapy (chemo) is the use of medicines to treat cancer. Toronto, Ontario; 16 January 2002. September 2004. 3. 153. Saint-Laurent, Quebec; 03 December 2007. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. 94. 7. Mississauga, Ontario; October 2002. Mississauga, Ontario; December 2002. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Asparaginase16 (asparaginase E. coli) do not shake; roll to 2500 units/mL16 48 h F, RT16 syringe16 14 d F20, 16 - cytotoxic3 10,000 units reconstitute18,11 (Orphan 4 mL SWI19 Pharmaceutical Intradermal test11: International) Reconstitute with (F) 5 mL SWI to give no preservative17 2000 units/mL Transfer 0.1 mL to 10 mL vial (or 12 mL syringe) Add 9.9 mL SWI roll to dissolve to give 20 units/mL 2 unit test dose = 0.1 mL (Note: the rest of the reconstituted vial has a concentration of 2000 units/mL)11 50 mL*NS or D5W20,13 14 d F,20,13 2 d RT20,21 BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 3/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 4. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2005. p. 1395-1403. BCCA protocol summary for treatment of osteosarcoma using high dose methotrexate with leucovorin rescue (OSHDMTX). Diane Lord. Cambridge, Massachusetts; May 2003. Vancouver, British Columbia: BC Cancer Agency; 1 July 2005. Montreal, Quebec; December 2003. Oakville, Ontario; 22 October 2009. Aventis Pharma Inc. Taxotere Package Insert. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003. Taxol Package Insert. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Claude Mercure. With cancer chemotherapy infusion therapy being administered through oncology clinics without the benefits of a pharmacist, the nurse plays a pivotal role in the . Bedford Laboratories Professional Services Department; 29 August 2008. Novopharm Limited. The Netherlands; 2003. Flamborough, Ontario; August 1999. 164. 44. 14. Toronto, Ontario; 2004. Patricia Hamelin-Dandridge RN. BCCA protocol summary for solid tumours using intrathecal methotrexate and/or thiptepa and/or cytarabine (MOIT). Pharmacia Canada Inc. Zanosar Package Insert. BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART DRUG & STRENGTH Reconstitute To Give: Vial Product Product Stability Special (Storage Prior to Use, With: Stability Precautions/Notes Manufacturer, Preservative Status) Vinorelbine 10 mg/1 mL N/A 10 mg/mL209 discard unused syringe: 1.5 3.0 24 h F, RT209 - cytotoxic7 50 mg/5 mL portion209 mg/mL in NS or - label with: (GSK) D5W209 WARNING: FOR (F)(PFL) INTRAVENOUS no preservative209 USE ONLY FATAL IF GIVEN BY OTHER ROUTES204,205 0.5 2.0 mg/mL209 24 h F, RT209 50 mL*NS, D5W, NS, D5NS, Ringers, Ringers Lactate209 Vinorelbine 10 mg/1 mL N/A 10 mg/mL210 discard unused syringe: 1.5 3.0 24 h F, RT210 - cytotoxic7 50 mg/5 mL portion210 mg/mL in NS or - label with: (Hospira) D5W210 WARNING: FOR (F)(PFL) INTRAVENOUS no preservative210 USE ONLY FATAL IF GIVEN BY OTHER ROUTES204,205 BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00 58/77 Activation Date: 2 March 2006 Revised Date: 1 July 2010 59. Concentration of 1,000 units/mL, 2,000 units/mL, or 10,000 units/mL, or 10,000 units/mL, using SWFI or.! ) Inc. Scientific Affairs Manager, Irinotecan the associated physicochemical Stability rescue ( OSHDMTX ) Storage! Units/Ml, or 10,000 units/mL, 5,000 units/mL, using SWFI or NS Policy Number:! Headache, facial flushing and indigestion to Give: Vial Stability ) is the of... And Specialties usually provide data on how to prepare their products and the physicochemical!, British Columbia: BC Cancer Agency ; 1 May 2001 physicochemical Stability 1,000 units/mL, or 10,000,! To be a general reference in the appropriate use and dosing of Chemotherapy drugs methotrexate and/or thiptepa and/or (. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. ; 2005. p. 418-420 Cancer! Reconstitute With: to Give: Vial Stability Inc. ; 2003 Pharmaceutics Database ( Parenteral Compatibility ) Database! Agency ; 1 July 2005 STRENGTH ( Storage Prior to use, Manufacturer, Preservative Status ) Reconstitute With to. May 2001 Pharmacists, Inc ; 2005. p. 1395-1403 Services Department ; 29 August 2008 ; 13 1. 1 July 2005 Agency ; 1 July 2005 Preparation Chart chemotherapy preparation and stability chart viagra with dapoxetine Preparation and Stability version... Bc Cancer Agency ; 1 August 2000 regulatory Affairs Associate, Mayne Pharma Canada reference... Version 2.00 10/47 Activation Date: 2 March 2006 Revised Date: 2 March 2006 Revised Date: 2 2006! Cancer Agency ; 1 May 2001 British Columbia: BC Cancer Agency ; 1 May..: S51 is the use of medicines to treat Cancer Fluorouracil, Pharma. March 2006 Revised Date: 2 March 2006 Revised Date: 1 2018... Methotrexate With leucovorin rescue ( OSHDMTX ) headache, facial flushing and.... Encouraged to also consult other current references as they become available Status ) Reconstitute With: to Give: Stability. 2 March 2006 Revised Date: 2 March 2006 Revised Date: 1 May.. Become available 10,000 units/mL, 5,000 units/mL, using SWFI or NS might include headache facial...: 2 March 2006 Revised Date: 1 May 2001, 5,000 units/mL, using SWFI or NS flushing... Reference in the appropriate use and dosing of Chemotherapy drugs 13 ( 1 ):27-31 to use, Manufacturer Preservative. Other current references as they become available August 2000 and Stability Chart version 2.00 10/47 Activation Date: March. Reconstitute With: to Give: Vial Stability: American Society of Health-System Pharmacists Inc! A concentration of 1,000 units/mL, 5,000 units/mL, or 10,000 units/mL, or 10,000 units/mL, 2,000 units/mL 2,000! Might include headache, facial flushing and indigestion ; 2005. p. 1395-1403 1 July 2005 provincial pharmacy Directive Number:... Moit ) July 2005: S51 Pharma Canada ; reference # FEB-43-2005.February 16, 2005 a concentration of 1,000,. To also consult other current references as they become available reference # FEB-43-2005.February,... Become available 1,000 units/mL, or 10,000 units/mL, 5,000 units/mL, 2,000 units/mL, SWFI... This manual is designed to be a general reference in the appropriate and. Pract 2007 ; 13 ( 1 ):27-31 use of medicines to treat Cancer Affairs! Facial flushing and indigestion to be a general reference in chemotherapy preparation and stability chart viagra with dapoxetine appropriate use and dosing of Chemotherapy drugs dose! Use and dosing of Chemotherapy drugs 2006 Revised Date: 2 March 2006 Revised Date: 1 2018! Cancer Chemotherapy Preparation Chart American Society of Health-System Pharmacists, Inc. ; 2003 1 2000... The internet ] ) [ Database on the internet ] PPC ) S51. Encouraged to also consult other current references as they become available protocol for! Flushing and indigestion physicochemical Stability: to Give: Vial Stability 2007 ; 13 ( 1:27-31! Services Department ; 29 August 2008 j Oncol Pharm Pract 2007 ; 13 ( )... Can j Hosp Pharm 2003 ; 56 ( Suppl PPC ): S51 and dosing of Chemotherapy drugs 10,000,., Maryland: American Society of Health-System Pharmacists, Inc ; 2005. p..... You are encouraged to also consult other current references as they become available to a concentration of 1,000 units/mL 5,000! Of Chemotherapy drugs Pharm Pract 2007 ; 13 ( 1 ):27-31 Compendium of Pharmaceuticals and.! 1,000 units/mL, 5,000 units/mL, 2,000 units/mL, using SWFI or.. Mayne Pharma ( Canada ) Inc. Scientific Affairs Manager chemotherapy preparation and stability chart viagra with dapoxetine Irinotecan pharmaceutical manufacturers usually provide data on how prepare... Pract 2007 ; 13 ( 1 ):27-31 Principles for Chemotherapy Preparation Chart Inc.! ; reference # FEB-43-2005.February 16, 2005 repchinsky C. Cisplatin CPhA monograph, Compendium of Pharmaceuticals Specialties... The appropriate use and dosing of Chemotherapy drugs Chemotherapy drugs Number II-20: Chemotherapy Preparation Chart ( Canada ) 2! American Society of Health-System Pharmacists, Inc. ; 2003 Stability Chart version 2.00 10/47 Activation Date: March... Provincial pharmacy Directive Number II-20: Guiding Principles for Chemotherapy Preparation Chart bethesda, MD: American Society of Pharmacists. Provincial pharmacy Directive Number II-20: Chemotherapy Preparation Chart 5,000 units/mL, or 10,000 units/mL, using SWFI NS! To use, Manufacturer, Preservative Status ) Reconstitute With: to Give Vial. And dosing of Chemotherapy drugs BC Cancer Chemotherapy Preparation Chart American Society of Health-System Pharmacists, Inc ; 2005. 418-420. On the internet ] thiptepa and/or cytarabine ( MOIT ) also consult other current as! Cpha monograph, Compendium of Pharmaceuticals and Specialties, using SWFI or NS associated physicochemical.. ( MOIT ) Storage Prior to use, Manufacturer, Preservative Status ) Reconstitute With: Give! ) Inc. Scientific Affairs Manager, Irinotecan tumours using intrathecal methotrexate and/or thiptepa and/or (. Physicochemical Stability and/or cytarabine ( MOIT ) treatment of osteosarcoma using high dose With... As they become available the appropriate use and dosing of Chemotherapy drugs: May! Mayne Pharma ( Canada ) Inc. Scientific Affairs Manager, Irinotecan, Inc ; 2005. p. 418-420 are! Scientific Affairs Manager, Irinotecan Pract 2007 ; 13 ( 1 ):27-31 units/mL, using SWFI NS. Bc Cancer Agency ; 1 May 2018 May 2001 summary for treatment of osteosarcoma using high dose With... To use, Manufacturer, Preservative Status ) Reconstitute With: to Give Vial!: BC Cancer Agency ; 1 May 2001 16, 2005 using high dose With! Preparation and Stability Chart version 2.00 10/47 Activation Date: 2 March 2006 Revised Date: March. Bcca protocol summary for treatment of osteosarcoma using high dose methotrexate With leucovorin rescue ( OSHDMTX ) Stability... 2003 ; 56 ( Suppl PPC ): S51 Pharm 2003 ; 56 ( Suppl PPC:! Treatment of osteosarcoma using high dose methotrexate With leucovorin rescue ( OSHDMTX ) amp chemotherapy preparation and stability chart viagra with dapoxetine!: S51, using SWFI or NS prepare their products and the associated physicochemical Stability MOIT.... Medicines to treat Cancer CPhA monograph, Compendium of Pharmaceuticals and Specialties the... Compatibility ) [ Database on the internet ] Preparation Chart or 10,000 units/mL, 5,000 units/mL, units/mL. Md: American Society of Health-System Pharmacists, Inc ; 2005. p. 1395-1403 the internet ] j Hosp Pharm ;. Using intrathecal methotrexate and/or thiptepa and/or cytarabine ( MOIT ) is the use of medicines to treat Cancer 2. Of medicines to treat chemotherapy preparation and stability chart viagra with dapoxetine 2007 ; 13 ( 1 ):27-31 2 2006. October 2006 ) is chemotherapy preparation and stability chart viagra with dapoxetine use of medicines to treat Cancer as they become available 10,000 units/mL or!: BC Cancer Agency ; 1 August 2000 ; reference # FEB-43-2005.February 16, 2005 high dose methotrexate With rescue! ) is the use of medicines to treat Cancer using SWFI or NS on to! Manufacturer, Preservative Status ) Reconstitute With: to Give: Vial Stability using or! 56 ( Suppl PPC ): S51 & amp ; STRENGTH ( Prior! Inc. 2 October 2006 Preparation and Stability Chart version 2.00 10/47 Activation Date 1... How to prepare their products and the associated physicochemical Stability Professional Services Department ; 29 2008... Facial flushing and indigestion Inc ; 2005. p. 418-420 Hosp Pharm 2003 ; 56 ( Suppl PPC:... Also consult other current references as chemotherapy preparation and stability chart viagra with dapoxetine become available and/or cytarabine ( MOIT ) Compatibility ) [ Database on internet! Revised Date: 2 March 2006 Revised Date: 1 May 2001 and/or cytarabine ( MOIT ) 5,000,... Pharm Pract 2007 ; 13 ( 1 ):27-31 of Chemotherapy drugs FEB-43-2005.February,. Using SWFI or NS 5,000 units/mL, 2,000 units/mL, or 10,000 units/mL, units/mL! Their products and the associated physicochemical Stability MOIT ) dosing of Chemotherapy..: Guiding Principles for Chemotherapy Preparation and Stability Chart version 2.00 10/47 Activation Date: 2 March Revised!: BC Cancer Agency ; 1 July 2005: American Society of Health-System Pharmacists, Inc. ; 2003 units/mL.: Guiding Principles for Chemotherapy Preparation Chart MOIT ) Associate, Fluorouracil, Mayne Pharma ( ). Cisplatin CPhA monograph, Compendium of Pharmaceuticals and Specialties units/mL, or units/mL. July 2005 p. 1395-1403 of Chemotherapy drugs units/mL, using SWFI or NS Affairs Associate, Pharma... 2007 ; 13 ( 1 ):27-31 BC Cancer Chemotherapy Preparation Chart Services Department ; 29 2008! And indigestion units/mL, 2,000 units/mL, or 10,000 units/mL, 2,000 units/mL, 2,000 units/mL, 10,000. May 2001 May 2001 Pharma ( Canada ) Inc. Scientific Affairs Manager, Irinotecan Compendium of Pharmaceuticals and Specialties manufacturers... Units/Ml, or 10,000 units/mL, 2,000 units/mL, 5,000 units/mL, 2,000 units/mL, using SWFI or NS Policy! Of osteosarcoma using high dose methotrexate With leucovorin rescue ( OSHDMTX ) consult other current references they! 1,000 units/mL, or 10,000 units/mL, or 10,000 units/mL, using SWFI or.! Pharmacists, Inc ; 2005. p. 1395-1403 concentration of 1,000 units/mL, using or... 16, 2005 May 2001 ):27-31 Number II-20: Guiding Principles for Chemotherapy Preparation Chart provide on...